Comparative in vitro activities of the new quinolone nemonoxacin (TG-873870), gemifloxacin and other quinolones against clinical isolates of Mycobacterium tuberculosis

被引：24

作者：

Tan, Che-Kim ^{[2
]}

Lai, Chih-Cheng ^{[3
]}

Liao, Chun-Hsing ^{[4
]}

Chou, Chien-Hong ^{[5
]}

Hsu, Hsiao-Leng ^{[1
]}

Huang, Yu-Tsung ^{[1
,6
]}

Hsueh, Po-Ren ^{[1
,6
]}

机构：

[1] Natl Taiwan Univ, Dept Lab Med, Natl Taiwan Univ Hosp, Coll Med, Taipei 10764, Taiwan

[2] Chi Mei Med Ctr, Dept Intens Care Med, Tainan, Taiwan

[3] Yi Min Hosp, Dept Internal Med, Taipei, Taiwan

[4] Far Eastern Mem Hosp, Dept Internal Med, Taipei, Taiwan

[5] Natl Taiwan Univ Hosp, Dept Internal Med, Yun Lin Branch, Yunlin, Taiwan

[6] Natl Taiwan Univ, Coll Med, Dept Internal Med, Natl Taiwan Univ Hosp, Taipei, Taiwan

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2009年 / 64卷 / 02期

关键词：

M; tuberculosis; TB; MDR-TB; FLUOROQUINOLONES; RESISTANCE; DELAYS;

D O I：

10.1093/jac/dkp174

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

引用

页码：428 / 429

页数：2

共 10 条

[1]

Carta Antonio, 2008, Anti-Infective Agents in Medicinal Chemistry, V7, P134, DOI 10.2174/187152108783954641

[2]

CHEN SJ, 2007, 45 ANN M IDSA SAN DI

[3] Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence [J].

Cole, ST ;

Brosch, R ;

Parkhill, J ;

Garnier, T ;

Churcher, C ;

Harris, D ;

Gordon, SV ;

Eiglmeier, K ;

Gas, S ;

Barry, CE ;

Tekaia, F ;

Badcock, K ;

Basham, D ;

Brown, D ;

Chillingworth, T ;

Connor, R ;

Davies, R ;

Devlin, K ;

Feltwell, T ;

Gentles, S ;

Hamlin, N ;

Holroyd, S ;

Hornby, T ;

Jagels, K ;

Krogh, A ;

McLean, J ;

Moule, S ;

Murphy, L ;

Oliver, K ;

Osborne, J ;

Quail, MA ;

Rajandream, MA ;

Rogers, J ;

Rutter, S ;

Seeger, K ;

Skelton, J ;

Squares, R ;

Squares, S ;

Sulston, JE ;

Taylor, K ;

Whitehead, S ;

Barrell, BG .

NATURE, 1998, 393 (6685) :537-+

[4] Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis [J].

Dooley, KE ;

Golub, J ;

Goes, FS ;

Merz, WG ;

Sterling, TR .

CLINICAL INFECTIOUS DISEASES, 2002, 34 (12) :1607-1612

[5] Fluoroquinolones, tuberculosis, and resistance [J].

Ginsburg, AS ;

Grosset, JH ;

Bishai, WR .

LANCET INFECTIOUS DISEASES, 2003, 3 (07) :432-442

[6] Extensively drug-resistant Mycobacterium tuberculosis during a trend of decreasing drug resistance from 2000 through 2006 at a medical center in Taiwan [J].

Lai, Chih-Cheng ;

Tan, Che-Kim ;

Huang, Yu-Tsung ;

Chou, Chien-Hong ;

Hung, Chien-Ching ;

Yang, Pan-Chyr ;

Luh, Kwen-Tay ;

Hsueh, Po-Ren .

CLINICAL INFECTIOUS DISEASES, 2008, 47 (07) :E57-E63

[7]

National Committee for Clinical Laboratory Standards, 2003, M24A NCCLS

[8] In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs [J].

Ruiz-Serrano, MJ ;

Alcalá, L ;

Martínez, L ;

Díaz, M ;

Marín, M ;

González-Abad, MJ ;

Bouza, E .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (09) :2567-2568

[9] Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas [J].

Wang, J-Y ;

Hsueh, P-R ;

Jan, I-S ;

Lee, L-N ;

Liaw, Y-S ;

Yang, P-C ;

Luh, K-T .

THORAX, 2006, 61 (10) :903-908

[10]

WHO, 2008, WHOHTMTB2008392

← 1 →